Protagenic Therapeutics, Inc.\new financial data

Symbol
PTIX, PTIXW on Nasdaq
Location
149 Fifth Avenue, Suite 500, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 35 % -90.5%
Debt-to-equity -207 % -89.5%
Return On Assets -303 % -73.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.93M shares
Common Stock, Shares, Outstanding 1.93M shares -59.7%
Entity Public Float 4.04M USD -54%
Common Stock, Value, Issued 195 USD -59.5%
Weighted Average Number of Shares Outstanding, Basic 1.85M shares -65.7%
Weighted Average Number of Shares Outstanding, Diluted 1.85M shares -65.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 3.9M USD +61.2%
General and Administrative Expense 2.34M USD +346%
Operating Income (Loss) -8.19M USD -126%
Nonoperating Income (Expense) -2.13M USD -244%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -10.3M USD -138%
Income Tax Expense (Benefit) -2.52K USD
Net Income (Loss) Attributable to Parent -10.3M USD -138%
Earnings Per Share, Basic 0 USD/shares +98.2%
Earnings Per Share, Diluted 0 USD/shares +98.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Marketable Securities, Current 1.59M USD -78.8%
Inventory, Net 1.08K USD
Assets, Current 2.86M USD +101%
Property, Plant and Equipment, Net 51.4K USD -40%
Intangible Assets, Net (Excluding Goodwill) 2.09M USD
Assets 5M USD +232%
Accounts Payable, Current 1.64M USD
Accrued Liabilities, Current 408K USD
Liabilities, Current 9.7M USD +1129%
Liabilities 9.7M USD +1129%
Accumulated Other Comprehensive Income (Loss), Net of Tax -130K USD -49.7%
Retained Earnings (Accumulated Deficit) -11.3M USD +67.4%
Stockholders' Equity Attributable to Parent -4.7M USD -90.3%
Liabilities and Equity 5M USD +232%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.17M USD -374%
Net Cash Provided by (Used in) Financing Activities 4.42M USD +359%
Net Cash Provided by (Used in) Investing Activities 943K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 1.93M shares -59.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -966K USD -112%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.72M USD +3713%
Deferred Tax Assets, Valuation Allowance 8.71M USD +23.2%
Deferred Tax Assets, Gross 8.71M USD +23.2%
Depreciation 62.9K USD +21.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -10.1M USD -159%
Property, Plant and Equipment, Gross 76.6K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 6.85M USD -80.8%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 108K USD -21.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%